サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1469148

エピジェネティクスの世界市場 - 産業規模、シェア、動向、機会、予測：製品・サービス別、技術別、エンドユーザー別、地域別、競合別（2019年～2029年）

Epigenetic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Technology, By End User, By Region and Competition, 2019-2029F
出版日: | 発行: TechSci Research | ページ情報: 英文 180 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

エピジェネティクスの世界市場 - 産業規模、シェア、動向、機会、予測：製品・サービス別、技術別、エンドユーザー別、地域別、競合別（2019年～2029年）
出版日: 2024年04月23日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のエピジェネティクスの市場規模は、2023年に17億5,000万米ドルに達し、2029年までのCAGRは8.05%で、予測期間中に目覚ましい成長を遂げると予測されています。 エピジェネティクス市場は、ゲノミクスと個別化医療の中で重要な分野であり、著しい成長と変容を経験しています。

エピジェネティクスは、DNAの塩基配列に変更を加えることなく遺伝子発現の遺伝的変化を研究するもので、さまざまな生物学的プロセスや疾患の進行において極めて重要な役割を果たしています。この市場には、エピジェネティクスの研究と応用に関連する技術、研究、サービスが含まれ、ヘルスケアと生物医学研究のランドスケープを再構築しています。

エピジェネティクス市場を促進する主な要因は、がんの発生率の増加です。エピジェネティクスな変化はがん細胞に広く見られ、腫瘍形成や疾患の進展に寄与しています。研究者や臨床医は、エピジェネティクス・プロファイリングを利用して、様々ながん種に関連する特定の修飾を同定し、個々の患者のエピジェネティクスなシグネチャーに合わせた標的療法の開発を可能にしています。世界のがん罹患率の上昇に伴い、正確なエピジェネティクス治療に対する需要は増加の一途をたどっており、市場拡大の原動力となっています。エピジェネティクス研究の進歩は市場成長に大きく寄与しています。次世代シーケンシングやDNAメチル化解析などの技術革新により、科学者はエピジェネティクス修飾を正確かつ大規模に探索できるようになりました。研究・診断ワークフローへのこれらの技術の統合は、バイオマーカー、治療標的、診断ツールの発見を加速し、市場を前進させています。

エピジェネティクス研究への資金提供の増加も重要な促進要因です。政府、民間、学術界の資金援助は、エピジェネティクス治療に焦点を当てた大規模プロジェクト、共同研究、臨床試験を支援しています。こうした投資は画期的な発見と革新を促し、研究成果を臨床応用に結びつけ、市場の成長を促進します。高齢者人口の増加もエピジェネティクス市場を牽引します。加齢は、加齢関連疾患の一因となる複雑なエピジェネティクス変化と関連しています。これらの変化を理解することは、疾患リスクを軽減するための介入策を開発する上で極めて重要であり、加齢に関連したエピジェネティクスな変化に対処する技術や治療に対する市場の需要を促進しています。

個別化医療の需要は、臨床現場におけるエピジェネティクスプロファイリングの採用を後押しします。エピジェネティクスバイオマーカーは、疾患感受性、予後、治療反応に関する洞察を提供し、個々の患者のエピジェネティクスプロファイルに基づくオーダーメイド治療を可能にします。個別化医療に向けたこの傾向は、革新的な診断アッセイや治療法の開発を促進し、エピジェネティクス市場を増強しています。エピジェネティクス市場は、技術の進歩、研究資金の増加、個別化医療への注力に牽引され、変革期を迎えています。エピジェネティクス研究と介入は、疾患の診断、治療、患者の転帰に革命をもたらす可能性があり、市場をヘルスケアと個別化医療を推進する重要な促進要因として位置づけています。

主な市場促進要因

エピジェネティクスへの資金提供の増加

個別化医療への需要

主な市場課題

エピジェネティクス制御の複雑さ

エピジェネティクスアッセイの標準化

倫理的・法的考慮事項

エピジェネティクスメカニズムの理解不足

主要市場動向

標的エピジェネティクス療法

エピゲノムバイオマーカー探索

医薬品開発におけるエピジェネティクスの統合

エピジェネティクス診断の増加

セグメント別洞察

技術別の洞察

製品・サービス別の洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のエピジェネティクス市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 製品・サービス別（キット試薬、酵素、機器アクセサリー、ソフトウェア、サービス）
    • 技術別（DNAメチル化、ヒストンメチル化、その他）
    • エンドユーザー別（学術・研究機関、製薬会社・バイオテクノロジー企業、受託研究機関、その他）
    • 地域別
    • 企業別（2023年）
  • 市場マップ
    • 製品・サービス別
    • 技術別
    • エンドユーザー別
    • 地域別

第5章 アジア太平洋のエピジェネティクス市場の展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 製品サービス別
    • 技術別
    • エンドユーザー別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第6章 欧州のエピジェネティクス市場の展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 製品サービス別
    • 技術別
    • エンドユーザー別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第7章 北米のエピジェネティクス市場の展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 製品サービス別
    • 技術別
    • エンドユーザー別
    • 国別
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 南米のエピジェネティクス市場の展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 製品サービス別
    • 技術別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第9章 中東・アフリカのエピジェネティクス市場の展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • 製品サービス別
    • 技術別
    • エンドユーザー別
    • 国別
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向・発展

  • 最近の動向
  • 製品発表
  • 合併・買収

第12章 世界のエピジェネティクス市場：SWOT分析

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Abcam Limited
  • Active Motif Inc
  • Hologic, Inc.
  • F Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc
  • Novartis AG
  • Element Biosciences
  • Dovetail Genomics LLC

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 22713

Global Epigenetic Marketwas valued at USD 1.75 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.05% through 2029.The Epigenetic Market, a crucial sector within genomics and personalized medicine, is experiencing remarkable growth and transformation. Epigenetics, the study of heritable changes in gene expression without altering the DNA sequence, plays a pivotal role in various biological processes and disease progression. This market encompasses technologies, therapies, and services related to epigenetic research and applications, reshaping healthcare and biomedical research landscapes.

A primary driver fueling the epigenetic market is the increasing incidence of cancer. Epigenetic alterations are prevalent in cancer cells, contributing to tumorigenesis and disease advancement. Researchers and clinicians utilize epigenetic profiling to identify specific modifications associated with various cancer types, enabling the development of targeted therapies tailored to individual patients' epigenetic signatures. With the global cancer burden rising, the demand for precise epigenetic treatments continues to grow, driving market expansion.Advancements in epigenetic research have significantly contributed to market growth. Innovations in technologies like next-generation sequencing and DNA methylation analysis enable scientists to explore epigenetic modifications accurately and at scale. Integration of these technologies into research and diagnostic workflows accelerates discovery of biomarkers, therapeutic targets, and diagnostic tools, propelling the market forward.

Increased funding for epigenetics research is another significant driver. Government, private, and academic funding supports large-scale projects, collaborative research, and clinical trials focused on epigenetic therapies. These investments foster groundbreaking discoveries and innovation, translating research findings into clinical applications and driving market growth.The rising geriatric population also drives the epigenetic market. Aging is associated with complex epigenetic changes contributing to age-related diseases. Understanding these modifications is crucial for developing interventions to mitigate disease risks, driving market demand for technologies and therapies addressing age-related epigenetic alterations.

The demand for personalized medicine boosts epigenetic profiling adoption in clinical practice. Epigenetic biomarkers offer insights into disease susceptibility, prognosis, and treatment response, enabling tailored treatments based on individual patients' epigenetic profiles. This trend toward personalized medicine fosters development of innovative diagnostic assays and therapies, augmenting the epigenetic market.The Epigenetic Market is undergoing transformative changes driven by technological advancements, increased research funding, and focus on personalized medicine. Epigenetic research and interventions hold promise for revolutionizing disease diagnosis, treatment, and patient outcomes, positioning the market as a key driver in advancing healthcare and personalized medicine.

Key Market Drivers

Growing funding for epigenetics

Increased funding for epigenetics research serves as a significant catalyst for driving growth in the epigenetic market. With greater financial support from governments, private organizations, and research institutions, scientists can conduct innovative studies to explore the intricacies of epigenetic regulation more comprehensively. These investments enable the development of advanced technologies, therapies, and diagnostic tools within the market. With substantial funding, researchers can delve into new epigenetic targets, expedite drug discovery processes, and enhance approaches to personalized medicine. Besides, financial backing encourages collaborative endeavors, facilitating the translation of research findings into practical applications. The availability of resources enhances research capabilities, thereby promoting market expansion and fostering breakthroughs in understanding and leveraging epigenetic mechanisms for diverse clinical and therapeutic purposes.

Demand for personalized medicine

The rising demand for personalized medicine is a significant driver of growth in the epigenetic market. Epigenetic modifications play a crucial role in tailoring treatment strategies to individual patients. With personalized medicine gaining traction, there is an increasing emphasis on understanding the unique epigenetic profiles of patients. Epigenetic profiling provides valuable insights into factors such as disease susceptibility, treatment response, and prognosis. By integrating this information with genomic and clinical data, healthcare providers can develop customized therapeutic interventions. Pharmaceutical companies are making substantial investments in epigenetic research to create targeted therapies that address patients' specific epigenetic profiles, leading to treatments that are both more effective and safer. As personalized medicine continues to gain prominence in healthcare, the epigenetic market experiences growing demand for its technologies and services, driving innovation and market expansion.

Key Market Challenges

Complexity of epigenetic regulation

The complexity of epigenetic regulation poses a significant challenge for the epigenetic market. Epigenetic mechanisms involve intricate processes such as DNA methylation, histone modifications, and non-coding RNA interactions, creating a multifaceted regulatory network. Understanding these complexities is essential for developing targeted therapies and diagnostic tools. However, deciphering the diverse interactions and their downstream effects on gene expression is a daunting task. Standardizing assays and interpreting epigenetic data accurately remain challenging due to the intricate nature of epigenetic regulation. Overcoming these complexities requires continuous research, innovative technologies, and multidisciplinary collaborations, ensuring reliable and reproducible results in epigenetic studies and applications, thereby advancing the epigenetic market.

Standardization of epigenetic assays

Standardization of epigenetic assays presents a significant challenge for the epigenetic market. Epigenetic research methods vary across laboratories and platforms, leading to inconsistencies in results. Differences in protocols, reagents, and data analysis hinder data comparability and reproducibility. Achieving uniformity is essential for reliable diagnostics and effective treatments. Developing standardized assays that ensure accurate, consistent, and reproducible outcomes is crucial. Overcoming this challenge requires collaborative efforts between researchers, industry experts, and regulatory bodies to establish common protocols and guidelines. Standardization efforts are vital to advancing the field, enhancing the reliability of epigenetic data, and fostering trust in epigenetic technologies, consequently driving the epigenetic market forward.

Ethical and legal considerations

Ethical and legal considerations pose a substantial challenge for the epigenetic market. Epigenetic research raises concerns about consent, privacy, and the potential misuse of genetic information. Ethical dilemmas arise regarding the disclosure of epigenetic data, especially in the context of predictive and personalized medicine. Legal frameworks often struggle to keep pace with the rapid advancements in epigenetic technologies, leading to ambiguities in regulations and patents. Addressing these challenges requires robust ethical guidelines, clear legislation, and transparent communication between stakeholders. Striking a balance between scientific progress, patient rights, and ethical principles is crucial for fostering public trust and ensuring the responsible growth of the epigenetic market.

Limited understanding of epigenetic mechanisms

The limited understanding of epigenetic mechanisms poses a formidable challenge for the epigenetic market. Despite significant progress, numerous aspects of epigenetic regulation remain elusive. Gaps in knowledge about specific modifications, their interactions, and their role in diseases hinder the development of targeted therapies and precise diagnostic tools. This lack of comprehensive understanding complicates research efforts, leading to uncertainties in therapeutic outcomes and diagnostic accuracy. Bridging these gaps requires extensive research, interdisciplinary collaborations, and innovative technologies. Advancements in genomics, epigenomics, and computational biology are crucial to unravel the complexities, enabling a deeper understanding of epigenetic mechanisms and driving the development of effective and reliable solutions within the epigenetic market.

Key Market Trends

Targeted epigenetic therapies

Targeted epigenetic therapies have emerged as a prominent trend in the epigenetic market. Unlike conventional treatments, these therapies focus on modifying specific epigenetic marks associated with diseases, enabling precise interventions. Advancements in epigenetic research have led to the development of drugs targeting enzymes and proteins involved in epigenetic regulation. These therapies hold immense potential for various conditions, including cancer, where aberrant epigenetic modifications play a significant role. By modulating gene expression patterns, targeted epigenetic therapies offer personalized and more effective treatment options. Pharmaceutical companies invest in research and development, driving innovation in this field, thereby reshaping the landscape of disease management and contributing to the growth of the epigenetic market.

Epigenomic biomarker discovery

Epigenomic biomarker discovery stands as a pivotal trend in the epigenetic market. Researchers are increasingly focusing on identifying specific epigenetic modifications associated with diseases, paving the way for precise diagnostics and targeted therapies. These biomarkers offer valuable insights into disease risk, progression, and treatment response. Advanced technologies, such as high-throughput sequencing and bioinformatics, empower scientists to analyze vast epigenomic datasets, accelerating biomarker discovery. Pharmaceutical companies and diagnostic firms are investing in these endeavors, driving innovation and the development of diagnostic assays. Epigenomic biomarkers not only enhance disease detection but also enable personalized treatment strategies, making them a cornerstone in the evolving landscape of healthcare and fueling the growth of the epigenetic market.

Integration of epigenetics in drug development

The integration of epigenetics in drug development has emerged as a transformative trend in the epigenetic market. Pharmaceutical companies are increasingly incorporating epigenetic research into their drug discovery processes. By understanding the role of epigenetic modifications in diseases, researchers can design targeted therapies, leading to more effective and safer treatments. Epigenetic insights enable the identification of novel drug targets and the development of precision medicines tailored to specific patient profiles. This trend fosters collaborations between academia and industry, driving innovation and accelerating the development of epigenetic drugs. The integration of epigenetics in drug development signifies a paradigm shift, offering promising avenues for personalized therapies and reshaping the future of medicine, thus propelling the epigenetic market forward.

Rise in epigenetic diagnostics

The rise in epigenetic diagnostics represents a significant trend in the epigenetic market. Advances in epigenomic profiling techniques enable the identification of unique epigenetic signatures associated with diseases, revolutionizing diagnostic approaches. Epigenetic biomarkers provide precise disease insights, aiding in early detection, prognosis, and treatment selection. These non-invasive, highly specific tests offer a deeper understanding of patients' conditions, allowing for personalized treatment strategies. Pharmaceutical companies and diagnostic laboratories invest in research and development, driving the commercialization of epigenetic diagnostic assays. The increasing adoption of epigenetic diagnostics signifies a paradigm shift towards more accurate, tailored healthcare solutions, fueling market growth and enhancing patient outcomes within the epigenetic market.

Segmental Insights

Technology Insights

Basedon the Technology, DNA methylation dominates the epigenetic market due to its pivotal role in regulating gene expression. Aberrant DNA methylation patterns are associated with various diseases, making them valuable diagnostic and therapeutic targets. Research focusing on understanding and manipulating DNA methylation marks has led to the development of innovative therapies and diagnostic tools. DNA methylation-based assays provide crucial insights into disease mechanisms, allowing for early detection and personalized treatment strategies. The precision and reliability of DNA methylation analysis have made it a cornerstone in epigenetic research, driving investments, collaborations, and commercialization efforts. Its versatility and significance position DNA methylation as a dominant force shaping the future of the epigenetic market.

Product Service Insights

Kits and reagents dominate the epigenetic market due to their essential role in enabling precise and efficient epigenetic research. Researchers rely on specialized kits and reagents to perform various epigenetic assays, such as DNA methylation analysis and chromatin immunoprecipitation. These products provide standardized protocols, ensuring accuracy and reproducibility in experiments. As demand for epigenetic studies grows, pharmaceutical companies, research institutions, and diagnostic labs heavily invest in these user-friendly and cost-effective solutions. The availability of comprehensive kits and high-quality reagents streamlines the research process, making them indispensable tools in laboratories worldwide. Their convenience, reliability, and widespread use establish kits and reagents as the dominant driving force in the epigenetic market.

Regional Insights

North America asserts dominance in the epigenetic market owing to its advanced healthcare infrastructure, substantial research funding, and a robust biotechnology sector. The region houses prominent pharmaceutical and biotech companies actively engaged in epigenetic research and drug development. Leading research institutions and universities, coupled with strategic collaborations between academia and industry, drive innovation in epigenetic technologies. Secondarily, supportive government policies, well-defined regulatory frameworks, and a high prevalence of chronic diseases fuel the demand for epigenetic diagnostics and therapies. The availability of skilled professionals and cutting-edge research facilities further solidify North America's position as a hub for epigenetic advancements, propelling its dominance in the global epigenetic market.

Key Market Players

Abcam Limited

Active Motif Inc

Hologic, Inc.

F Hoffmann-La Roche Ltd.

Illumina, Inc.

Qiagen N.V.

Thermo Fisher Scientific Inc

Novartis AG

Element Biosciences

Dovetail Genomics LLC

Report Scope:

In this report, the Global Epigenetic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epigenetic Market,By Product Service:

  • Kits Reagents
  • Enzymes
  • Instruments Accessories
  • Software
  • Services

Epigenetic Market,By Technology:

  • DNA Methylation
  • Histone Methylation
  • Others

Epigenetic Market,By End user:

  • Academic and Research Institutes
  • Pharmaceutical Companies and Biotechnology Companies
  • Contract Research Organizations
  • Others

Epigenetic Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Epigenetic Market.

Available Customizations:

Global Epigenetic marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Epigenetic Market Outlook

  • 4.1.Market Size Forecast
    • 4.1.1.By Value
  • 4.2.Market Share Forecast
    • 4.2.1.By Product Service (Kits Reagents, Enzymes, Instruments Accessories, Software, Services)
    • 4.2.2.By Technology (DNA Methylation, Histone Methylation, Others)
    • 4.2.3.By End User (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, Contract Research Organizations, Others)
    • 4.2.4.By Region
    • 4.2.5.By Company (2023)
  • 4.3.Market Map
    • 4.3.1.By Product Service
    • 4.3.2.By Technology
    • 4.3.3.By End user
    • 4.3.4.By Region

5.Asia Pacific Epigenetic Market Outlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Product Service
    • 5.2.2.By Technology
    • 5.2.3.By End user
    • 5.2.4.By Country
  • 5.3.Asia Pacific: Country Analysis
    • 5.3.1.China Epigenetic Market Outlook
      • 5.3.1.1.Market Size Forecast
        • 5.3.1.1.1.By Value
      • 5.3.1.2.Market Share Forecast
        • 5.3.1.2.1.By Product Service
        • 5.3.1.2.2.By Technology
        • 5.3.1.2.3.By End user
    • 5.3.2.India Epigenetic Market Outlook
      • 5.3.2.1.Market Size Forecast
        • 5.3.2.1.1.By Value
      • 5.3.2.2.Market Share Forecast
        • 5.3.2.2.1.By Product Service
        • 5.3.2.2.2.By Technology
        • 5.3.2.2.3.By End user
    • 5.3.3.Australia Epigenetic Market Outlook
      • 5.3.3.1.Market Size Forecast
        • 5.3.3.1.1.By Value
      • 5.3.3.2.Market Share Forecast
        • 5.3.3.2.1.By Product Service
        • 5.3.3.2.2.By Technology
        • 5.3.3.2.3.By End user
    • 5.3.4.Japan Epigenetic Market Outlook
      • 5.3.4.1.Market Size Forecast
        • 5.3.4.1.1.By Value
      • 5.3.4.2.Market Share Forecast
        • 5.3.4.2.1.By Product Service
        • 5.3.4.2.2.By Technology
        • 5.3.4.2.3.By End user
    • 5.3.5.South Korea Epigenetic Market Outlook
      • 5.3.5.1.Market Size Forecast
        • 5.3.5.1.1.By Value
      • 5.3.5.2.Market Share Forecast
        • 5.3.5.2.1.By Product Service
        • 5.3.5.2.2.By Technology
        • 5.3.5.2.3.By End user

6.Europe Epigenetic Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Product Service
    • 6.2.2.By Technology
    • 6.2.3.By End user
    • 6.2.4.By Country
  • 6.3.Europe: Country Analysis
    • 6.3.1.France Epigenetic Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Product Service
        • 6.3.1.2.2.By Technology
        • 6.3.1.2.3.By End user
    • 6.3.2.Germany Epigenetic Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Product Service
        • 6.3.2.2.2.By Technology
        • 6.3.2.2.3.By End user
    • 6.3.3.Spain Epigenetic Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Product Service
        • 6.3.3.2.2.By Technology
        • 6.3.3.2.3.By End user
    • 6.3.4.Italy Epigenetic Market Outlook
      • 6.3.4.1.Market Size Forecast
        • 6.3.4.1.1.By Value
      • 6.3.4.2.Market Share Forecast
        • 6.3.4.2.1.By Product Service
        • 6.3.4.2.2.By Technology
        • 6.3.4.2.3.By End user
    • 6.3.5.United Kingdom Epigenetic Market Outlook
      • 6.3.5.1.Market Size Forecast
        • 6.3.5.1.1.By Value
      • 6.3.5.2.Market Share Forecast
        • 6.3.5.2.1.By Product Service
        • 6.3.5.2.2.By Technology
        • 6.3.5.2.3.By End user

7.North America Epigenetic Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Product Service
    • 7.2.2.By Technology
    • 7.2.3.By End user
    • 7.2.4.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States Epigenetic Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Product Service
        • 7.3.1.2.2.By Technology
        • 7.3.1.2.3.By End user
    • 7.3.2.Mexico Epigenetic Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Product Service
        • 7.3.2.2.2.By Technology
        • 7.3.2.2.3.By End user
    • 7.3.3.Canada Epigenetic Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Product Service
        • 7.3.3.2.2.By Technology
        • 7.3.3.2.3.By End user

8.South America Epigenetic Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Product Service
    • 8.2.2.By Technology
    • 8.2.3.By End user
    • 8.2.4.By Country
  • 8.3.South America: Country Analysis
    • 8.3.1.Brazil Epigenetic Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Product Service
        • 8.3.1.2.2.By Technology
        • 8.3.1.2.3.By End user
    • 8.3.2.Argentina Epigenetic Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Product Service
        • 8.3.2.2.2.By Technology
        • 8.3.2.2.3.By End user
    • 8.3.3.Colombia Epigenetic Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Product Service
        • 8.3.3.2.2.By Technology
        • 8.3.3.2.3.By End user

9.Middle East and Africa Epigenetic Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Product Service
    • 9.2.2.By Technology
    • 9.2.3.By End user
    • 9.2.4.By Country
  • 9.3.MEA: Country Analysis
    • 9.3.1.South Africa Epigenetic Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Product Service
        • 9.3.1.2.2.By Technology
        • 9.3.1.2.3.By End user
    • 9.3.2.Saudi Arabia Epigenetic Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Product Service
        • 9.3.2.2.2.By Technology
        • 9.3.2.2.3.By End user
    • 9.3.3.UAE Epigenetic Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Product Service
        • 9.3.3.2.2.By Technology
        • 9.3.3.2.3.By End user

10.Market Dynamics

  • 10.1.Drivers
  • 10.2.Challenges

11.Market Trends Developments

  • 11.1.Recent Developments
  • 11.2.Product Launches
  • 11.3.Mergers Acquisitions

12.Global Epigenetic Market: SWOT Analysis

13.Porter's Five Forces Analysis

  • 13.1.Competition in the Industry
  • 13.2.Potential of New Entrants
  • 13.3.Power of Suppliers
  • 13.4.Power of Customers
  • 13.5.Threat of Substitute Product

14.Competitive Landscape

  • 14.1.Abcam Limited
    • 14.1.1.Business Overview
    • 14.1.2.Company Snapshot
    • 14.1.3.Product Services
    • 14.1.4.Financials (In case of listed)
    • 14.1.5.Recent Developments
    • 14.1.6.SWOT Analysis
  • 14.2.Active Motif Inc
  • 14.3.Hologic, Inc.
  • 14.4.F Hoffmann-La Roche Ltd.
  • 14.5.Illumina, Inc.
  • 14.6.Qiagen N.V.
  • 14.7.Thermo Fisher Scientific Inc
  • 14.8.Novartis AG
  • 14.9.Element Biosciences
  • 14.10.Dovetail Genomics LLC

15.Strategic Recommendations

16.About Us Disclaimer